J&J breast cancer test
This article was originally published in The Gray Sheet
Executive Summary
Veridex unit will launch CellSearch metastatic breast cancer diagnostic system in the fall of 2004. During the American Society of Clinical Oncology meeting in New Orleans June 5, Johnson & Johnson explained that the CellSearch test - which identifies and counts circulating tumor cells in whole blood samples to predict progression-free and overall survival in metastatic breast cancer patients - should help physicians determine cancer treatment effectiveness much earlier than current methods, which can take up to three months. CellSearch will compete with products like ViroLogic's eTag molecular cancer assay in the burgeoning field of personalized medicine for oncology diseases (1"The Gray Sheet" June 7, 2004, p. 18)...
You may also be interested in...
ViroLogic Gets Molecular Cancer Test Platform With Aclara
ViroLogic will leverage its established HIV resistance test infrastructure to commercialize Aclara's eTag molecular cancer assay platform under a $200 mil. definitive acquisition agreement, announced June 1
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.